J&J Medical Connect
Immunology
Immunology

Congress Materials - Neuromuscular Study Group Scientific Meeting (NMSG 2026)

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Corticosteroid usage in patients with generalized myasthenia gravis receiving nipocalimab: Phase 3 VIVACITY-MG3 open-label extension

Jelena Stojanovic-Radic, Yuebing Li, Kavita Gandhi, Wisam Karmous, Marie Fitzgibbon, Ibrahim Turkoz, I-Ching Tsai, Zia Choudhry, Wim Noel, Louis Jackson, Sindhu Ramchandren, Hiroyuki Murai


View poster

Long-term safety and efficacy of nipocalimab: Approximately 2 years follow-up results from VIVACITY-MG3 open-label extension

David Hutcheson, Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard J Nowak, Constantine Farmakidis, Vera Bril, Jan De Bleecker, Huan Yang, Eduard Minks, Jin-Sung Park, Mariusz Grudniak, Marek Smilowski, Teresa Sevilla, Sarah Hoffmann, Kumaraswamy Sivakumar, Panna Sanga, Ibrahim Turkoz, Yaowei Zhu, Marie Fitzgibbon, Michel Burcklen


View poster

Pregnancy Enhanced Tracking with Neonatal and Infant Assessment (PETUNIA): Design of a safety study for nipocalimab in generalized myasthenia gravis

Ashley Anderson, Neelam Goyal, Christopher J Robinson, Christiane Schneider-Gold, Diana E Clements, Marie Fitzgibbon, Ibrahim Turkoz, Lorraine S Gentner, Toyin Adewole, Lisa Schwartz, Melanie H Jacobson


View poster

View plain language summary

Quality of life in patients with generalized myasthenia gravis achieving sustained vs transient minimal symptom expression in the Phase 3 VIVACITY-MG3 trial

Kathryn Bercury-Russell, Elena Cortés Vicente, Nolan Campbell, Kavita Gandhi, Marie Fitzgibbon, Ibrahim Turkoz


View poster

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.